General Comments / Chat, page-8921

Are we going to drop EMD AML, in priority for R/R AML, which also collects EMD data?

Assuming if Bisantrene is approved for AML can be used even if EMD is present?

Should we drop multi-drug combo trials for R/R AML for both Decitabine and Venetoclax without a drug supply agreement from both?

Is it just a strategy to run both trials to get interest or are they actually going to follow through with both?

To me it makes sense to get approval with one indication and drug combo once approved expand out. That means commercially dropping one?

Consider MD Anderson a donation, change in EMD SOC is going to be a costly long hard road and likely lead to a dead end IMO, unless we partner with Pharma who wants it then they can assist with biobucks and advancing programs. EMD quickly becoming a pipe dream just like NPP, albeit a great idea when it started out.

ASH 2023 and Sheba 2 results will get some traction shortly and provide greater focus for R/R AML.

Thoughts only waiting on the program update.